Gefitinib: impact on survival benefit

DOI 25 References
  • Takeda Masayuki
    Shien Lab., National Cancer Center Hospital, Pharmacology Division, National Cancer Research Institute
  • Nishio Kazuto
    Shien Lab., National Cancer Center Hospital, Pharmacology Division, National Cancer Research Institute

Bibliographic Information

Other Title
  • がんの分子標的治療　　ゲフィチニブ（イレッサ）の動向

Search this article

Description

Gefitinib is an orally active, selective tyrosine kinase inhibitor that block EGFR transduction pathway. On the some phase III trails of gefitinib therapy, it failed to show survival benefit but EGFR mutations were correlated with gefitinib responses.

Journal

  • Drug Delivery System

    Drug Delivery System 21 (1), 58-63, 2006

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(25)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top